SHS invests 10 million euros in Simulands

SHS Gesellschaft für Beteiligungsmanagement, headquartered in the city of Tübingen in south-west Germany, has invested a sum of 10 million euros in the Zurich-based firm Simulands AG. This should allow the manufacturer of simulators for cardiovascular interventions to accelerate its commercialization activities, further details of which can be found in a press release.

Since 2019, Simulands has been developing and producing devices that doctors can use to simulate and practice procedures on patients’ hearts. The company’s mission is to minimize training and research directly on patients and animals in the cardiovascular field.

To achieve this, the simulators have human proportions and a realistic feel and enable cardiologists and their teams to train for complex cardiovascular interventions with real devices such as cardiac catheters for minimally invasive treatments. The training should facilitate improved treatment results in addition to enhancing patient safety.

The participation in Simulands AG is the first investment from the SHS’s recently launched sixth generation fund. For the new fund, the Tübingen-based company is looking for other innovative, high-growth healthcare companies “that can make a real difference in healthcare”.

SHS is a provider of equity capital that goes towards investments in healthcare companies in Europe. The focus of the investments is on expansion financing, shareholder changes and succession situations. “Partnering with SHS is an invaluable opportunity for Simulands to accelerate its entry to key global markets”, comments Andrea Guidotti, CEO of Simulands, in the press release. ko